Suprachoroidal Hemorrhage Associated With Pars Plana Vitrectomy
Sponsor
Beijing Tongren Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT05013281
Collaborator
(none)
28
1
132.9
0.2
Study Details
Study Description
Brief Summary
To analyze the characteristics, related risk factors, and prognosis of suprachoroidal hemorrhage (SCH) associated with pars plana vitrectomy (PPV).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Actual Enrollment
:
28 participants
Observational Model:
Case-Only
Time Perspective:
Retrospective
Official Title:
Suprachoroidal Hemorrhage Associated With Pars Plana Vitrectomy
Actual Study Start Date
:
Jan 1, 2010
Actual Primary Completion Date
:
Jun 30, 2020
Actual Study Completion Date
:
Jan 28, 2021
Outcome Measures
Primary Outcome Measures
- pathogenesis [baseline]
pathogenesis of PPV-related SCH and incidence of PPV-related SCH
Secondary Outcome Measures
- vision acuity [up to 7 weeks]
the final vision acuity
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- Suprachoroidal hemorrhage associated with pars plana vitrectomy
Exclusion Criteria:
- Patients with eye trauma-related Suprachoroidal hemorrhage were excluded.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Beijing Tongren Hospital | Beijing | Beijing | China | 100730 |
Sponsors and Collaborators
- Beijing Tongren Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Beijing Tongren Hospital
ClinicalTrials.gov Identifier:
NCT05013281
Other Study ID Numbers:
- TR2021SCH
First Posted:
Aug 19, 2021
Last Update Posted:
Aug 19, 2021
Last Verified:
Jul 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: